Clinical trials: Thrombo-embolism
Heart Failure, Respiratory Insufficiency
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in…
- Conditions
- Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases
- Trial name
- MARINER (NCT02111564)
- Testing
- Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg
- Where
- 593 sites in United States, Argentina and 35 more
- Volunteers
- 12,024 people
- Sponsor
- Janssen Research & Development, LLC
Thromboembolism
Secondary Prevention of Venous Thrombo Embolism (VTE).
The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR) of 2.0-3.0) for the long-term treatment and…
- Trial name
- RE-MEDY (NCT00329238)
- Testing
- Dabigatran, Warfarin
- Where
- 275 sites in United States, Argentina and 31 more
- Volunteers
- 2,867 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism, Pulmonary Embolism
Exclusion of Venous Thrombo-Embolism With a New Clinical Decision Support
The goal of this non interventional study is to demonstrate the diagnostic performances on fresh plasmas in comparison with the performances on frozen plasmas in any patients with VTE suspicion, whatever the pre-test probability.
- Conditions
- Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis
- Trial name
- EXTEND (NCT06480994)
- Testing
- Routine Assays on fresh plasma, New Clinical Decision Support on fresh plasma, New Clinical Decision Support on frozen plasma
- Where
- 4 sites in France
- Volunteers
- 1,836 people
- Sponsor
- Diagnostica Stago R&D
Venous Thromboembolism
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.
The purpose of this study is to assess if 10 mg BAY59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.
- Trial name
- RECORD 4 (NCT00362232)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 124 sites in United States, Bulgaria and 11 more
- Volunteers
- 3,148 people
- Sponsor
- Bayer
Pulmonary Thrombo-embolism
A Safety and Efficacy Study for Implantation and Retrieval Procedures Using the VENATECH® Retrieval Filter System
To establish the clinical safety and efficacy of the VenaTech® Retrievable Vena Cava Filter
- Trial name
- NCT02674672
- Testing
- VenaTech® (VenaTech Retrievable Filter)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- B.Braun Médical - CoE Chasseneuil
Neoplasms, Venous Thromboembolism
National Evaluation of the Adherence to Recommendations of Venous Thrombo Embolism Treatment in Cancer Patients
Treatment of venous thromboembolism in cancer patients is specific and has been validated in trials that favor the use of LMWH (Low Molecular Weight Heparin) instead of VKA (Vitamin K Antagonist) treatment during 6 months.
- Trial name
- CARMEN (NCT01362933)
- Testing
- VTE treatment in cancer patient description
- Where
- 49 sites in France
- Volunteers
- 502 people
- Sponsor
- Floralis